Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C24H24FN3O2 |
| Molecular Weight | 405.4647 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=CC=CC(CNC(=O)CC2=NC=C(C=C2)C3=CC=C(C=C3)N4CCOCC4)=C1
InChI
InChIKey=CMKKPJNMYLOUCE-UHFFFAOYSA-N
InChI=1S/C24H24FN3O2/c25-21-3-1-2-18(14-21)16-27-24(29)15-22-7-4-20(17-26-22)19-5-8-23(9-6-19)28-10-12-30-13-11-28/h1-9,14,17H,10-13,15-16H2,(H,27,29)
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
897016-26-1
Created by
admin on Sat Dec 16 11:28:31 UTC 2023 , Edited by admin on Sat Dec 16 11:28:31 UTC 2023
|
PRIMARY | |||
|
KX2-361
Created by
admin on Sat Dec 16 11:28:31 UTC 2023 , Edited by admin on Sat Dec 16 11:28:31 UTC 2023
|
PRIMARY | MedKoo CAT NO.: 206196; CAS NO.: 897016-26-1Description: KX02, also known as KX2-361, is a lipophilic, orally available inhibitor of both Src kinase activity and tubulin polymerization, with potential antineoplastic activity. Upon oral administration, src/tubulin inhibitor KX02 binds to and inhibits the activity of Src kinase. This inhibits both downstream signaling and the proliferation of Src kinase-expressing tumor cells. KX02 also binds to tubulin heterodimers and inhibits microtubule polymerization, thereby disrupting microtubule formation, mitosis, and further proliferation. (Last updated: 5/6/2016) | ||
|
RVW387BA9U
Created by
admin on Sat Dec 16 11:28:31 UTC 2023 , Edited by admin on Sat Dec 16 11:28:31 UTC 2023
|
PRIMARY | |||
|
C120101
Created by
admin on Sat Dec 16 11:28:31 UTC 2023 , Edited by admin on Sat Dec 16 11:28:31 UTC 2023
|
PRIMARY | |||
|
KX2-361
Created by
admin on Sat Dec 16 11:28:31 UTC 2023 , Edited by admin on Sat Dec 16 11:28:31 UTC 2023
|
PRIMARY | Official Title: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional TherapiesPurpose: The purpose of this study is to determine the safety and tolerability of the study drug KX2-361 and to determine how much of the study drug enters the bloodstream, in patients with advanced malignancies that have not responded to conventional therapies. | ||
|
11545920
Created by
admin on Sat Dec 16 11:28:31 UTC 2023 , Edited by admin on Sat Dec 16 11:28:31 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
